Camps-Renom, P, Guasch-Jiménez, M, Martinez-Domeño, A, Prats-Sánchez, L, Ramos-Pachón, A, Alvarez-Cienfuegos, J, Silva, Y, Fortea-Cabo, G, Morales-Caba, L, Rodríguez-Campello, A, Giralt-Steinhauer, E, Flores, A, Ustrell, X, López-Hernández, N, Corona-García, DJ, Freijo-Guerrero, MM, Luna, A, Tejada-Meza, H, Marta-Moreno, J, Moniche, F, Pardo-Galiana, B, Castellanos, M, Albert-Lacal, L, Sanz-Monllor, A, Aguilera-Simón, A, Marín, R, Ezcurra-Díaz, G, Lambea-Gil, A, Marti-Fàbregas, J. A Randomized Trial on Hemodynamic Optimization of Cerebral Perfusion after Successful Endovascular Therapy in Patients with Acute Ischemic Stroke (HOPE). CEREBROVASCULAR DISEASES. 2025; 54(4)DOI:10.1159/000540606. PMID:39208776. IF:1.500(Q3/8D).

Font, MA, García-Sánchez, SM, Mengual, JJ, Avellaneda, C, Boned, S, Doncel-Moriano, A, Urra, X, Camps-Renom, P, de la Ossa, NP, Terceño, M, Yugueros, B, Ustrell, X, Purroy, F, Rodríguez-Campello, A, Molina, C, Krupinski, J, Aguirre, GF, Baraldes, M, Jiménez-Fàbrega, X, Salvat-Plana, M, Elosua, R, Abilleira, S, Cardona, P, Gómez-Choco, M. Early neurological deterioration before endovascular treatment in patients with mild stroke. MINORCAT-END-EVT study. Journal of Stroke & Cerebrovascular Diseases. 2026; 35(3)DOI:10.1016/j.jstrokecerebrovasdis.2026.108584. PMID:41679406. IF:1.800(Q3/7D).

Montalvo, C, Garcia-Tornel, A, Olive-Gadea, M, Rodrigo-Gisbert, M, Requena, M, Rizzo, F, Rodriguez-Luna, D, Rodriguez-Villatoro, N, Pagola, J, Simonetti, R, de la Ossa, NP, Camps-Renom, P, Canovas, D, Flores, A, Rodriguez-Campello, A, Silva, Y, Urra, X, Purroy, F, Bustamante, A, Salvat-Plana, M, Cardona, P, Molina, C, Rubiera, M, Ribo, M. Socioeconomic Deprivation in Ischemic Stroke Treated With Endovascular Thrombectomy: Not All Recoveries Are Equal. STROKE. 2026; 57(2)DOI:10.1161/STROKEAHA.125.052865. PMID:41208686. IF:8.900(Q1/1D).

Tiedt, S, Bustamante, A, Cameron, A, Camps-Renom, P, Grosse, GM, Ospel, J, Volbers, B, Audebert, HJ, Aulin, J, Cheng, BS, Cordonnier, C, Coutinho, JM, Fonseca, AC, Hill, MD, Jensen, M, Jern, C, Kamtchum-Tatuene, J, Katan, M, Kelly, PJ, Kopczak, A, Lemmens, R, Lindgren, AG, Loan, JJM, Nolte, CH, Puy, L, Saba, L, Salman, RA, Sandset, EC, Selim, MH, Seners, P, Sprigg, N, Tsai, HH, Doyle, KM, Montaner, J, Schreuder, FHBM, Sposato, L, Samarasekera, N, Mccabe, JJ. Biomarkers for advancing diagnosis and prognosis in stroke. LANCET NEUROLOGY. 2026; 25(4)DOI:10.1016/S1474-4422(25)00480-6. PMID:41864237. IF:45.500(Q1/1D).

Dietz, S, Avula, A, Kumar, A, Petersen, N, Guasch-Jimenez, M, Slowik, A, Wrona, P, Dhar, R. White Matter Hyperintensities Are Associated with Worse Outcomes but Not Greater Cerebral Edema or Hemorrhagic Transformation After Large Vessel Occlusion Stroke. STROKE. 2026; 57(SUPPL_1)DOI:10.1161/str.57.suppl_1.DP035. PMID:. IF:8.900(Q1/1D).

de Sousa, DA, Katsanos, AH, Li, LX, Martinez-Majander, N, McCabe, J, Palaiodimou, L, Pachon, AR, Romoli, M, Schellinger, PD, Zietz, A, Poli, S, Roaldsen, M, Shoamanesh, A, Sykora, M, Tsivgoulis, G. ESO annual stroke evidence update 2025. European Stroke Journal. 2026; 11(2)DOI:10.1093/esj/aakag009. PMID:41706824. IF:4.500(Q1/2D).

Cortés-Vicente, E, Guerrero, A, Díaz, C, Martínez, E, Toja-Camba, FJ, Abad, MR, Serra, JM, Trillo, JL, Machín, CM, Gil, A. Assessing the Value Contribution of Vyvgart® (Efgartigimod Alfa) in the Treatment of Generalized Myasthenia Gravis with Acetylcholine Receptor Antibody in Spain Through Multi-criteria Decision Analysis (Jan, 10.1007/s12325-026-03490-x, 2026). ADVANCES IN THERAPY. 2026; 43(5)DOI:10.1007/s12325-026-03532-4. PMID:41817916. IF:4.000(Q1/3D).

Campos-Lucas, FJ, Cortés-Vicente, E, Guerrero-Sola, A, Alvarez-Velasco, R, Pardo-Gómez, R, Gómez-Salgado, J, Antón-Rodríguez, C, Caballero-Martínez, F. Patient Perceptions of Needs and Expectations Regarding the Current Management of Myasthenia Gravis: A Biopsychosocial Study. Neurology and Therapy. 2026; 15(3)DOI:10.1007/s40120-026-00892-5. PMID:41721962. IF:4.800(Q1/2D).